BPC-157 and TB-500 (Wolverine Stack): What the New HHS Policy Actually Means

The HHS policy is temporary enforcement discretion. It is not an FDA approval. Under the notice, HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" who compounds a drug product with a peptide bulk substance listed in the policy's Appendix A.

Per the HHS policy document, Appendix A lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The policy sets ten conditions, and condition 7 matters most for Wolverine: each compounded product may contain only a single active ingredient from Appendix A. So separate BPC-157 and TB-500 prescriptions may fit the policy. A single "Wolverine" vial with both peptides does not.

The Federal Register text says it plainly: compounded drugs "are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed." HHS also says it may revisit the policy "if… a safety signal or product quality issue arises."

BPC-157 ("body protection compound") is a 15-amino-acid peptide fragment first studied from a protein found in gastric juice. TB-500 is a synthetic peptide based on a fragment of thymosin beta-4, a protein involved in cell movement and tissue repair. People call the pair "Wolverine" because of claims about faster recovery. Those claims come mostly from animal and lab studies.

BPC-157 — What it is: Synthetic 15-amino-acid peptide (gastric-protein fragment) — FDA-approved product? No — Routes in HHS policy (Appendix B): BPC-157 acetate: subcutaneous, intramuscular, oral, topical — Main evidence base: Rodent and cell studies; small human safety pilots — Fits HHS condition 7 (single API)? Yes, as a single-peptide Rx. TB-500 — What it is: Synthetic fragment based on thymosin beta-4 — FDA-approved product? No — Routes in HHS policy (Appendix B): TB-500 acetate: subcutaneous or intramuscular injection only — Main evidence base: Mostly animal and cell studies of thymosin beta-4 — Fits HHS condition 7 (single API)? Yes, as a single-peptide Rx. "Wolverine" stack — BPC-157 + TB-500 used together — FDA-approved product? No — Routes: Not covered as one combined product — Main evidence base: No controlled human trials of the combination — Fits HHS condition 7 (single API)? No as a one-vial blend.

There is no FDA-approved BPC-157 or TB-500 product. That means there is no approved label, no reference standard, and no approved dose to compare against. The middle column below summarizes conditions 3–10 of the HHS policy.

FDA reviews safety/efficacy before sale — FDA-approved drug (general): Yes — 503A compounded single peptide under HHS policy: No — Research-use-only (RUO) peptide: No. Prescription for a specific patient — Yes (if Rx drug) — Required — None. Bulk ingredient source — Approved manufacturing process — FDA-registered (§510) original manufacturer under CGMP, with a valid CoA; repackers must validate both (conditions 3–4) — Unknown; often unverified. Active ingredients per product — Per label — One API from Appendix A (condition 7) — Anything, often blends. Serious adverse-event reporting — Required by manufacturer — Serious AEs and product-quality problems reported to MedWatch; labeling explains how to report (condition 5) — None. Label — FDA-approved labeling — "This is a compounded drug product. Not for resale." (condition 6) — "Not for human consumption".

HHS published an enforcement-discretion notice on Oct 30, 2026 — Established (Federal Register; HHS policy document). BPC-157 and TB-500 are now FDA-approved — False. Discretion is not approval. The policy is permanent — False. HHS calls it interim and says it may revisit it. It covers 503B outsourcing facilities — No. The notice covers 503A compounding. It makes RUO "research chemicals" legal for people — No. It covers a combined BPC-157 + TB-500 vial — No. HHS condition 7 requires a single API. BPC-157 speeds tendon, ligament, and muscle healing in humans — Unproven. Mostly rodent data (Gwyer et al., 2019). BPC-157 is well tolerated in people — Emerging. Only very small pilot data (IV BPC-157 pilot). Wolverine works better than either peptide alone — Unknown. No human combination trials.

Evidence for each ingredient alone is not evidence for the combination.

Possible tissue-repair signals. In animal models, BPC-157 has been linked to tendon, ligament, muscle, and gut healing. Thymosin beta-4 has been studied for wound repair and cell migration.

A more regulated path than RUO. Under the policy, a patient-specific prescription, a state-licensed pharmacy, an FDA-registered CGMP manufacturer, and a CoA add guardrails that gray-market vials do not have. HHS says one aim of the policy is to discourage use of research-use-only peptides from foreign sources.

Clinician oversight. A prescription means someone reviews your history, medications, and goals, and watches for side effects.

What we can't honestly say: that these peptides will heal your injury faster, replace physical therapy or surgery, or improve performance. Controlled human trials have not shown that.

Human data are thin, so there are no reliable trial rates to report. The table below lists reported or plausible concerns, not measured frequencies. Injection-site redness, pain, swelling — Commonly reported with injectable peptides. Infection or contamination — Higher risk with non-sterile or RUO sources. Wrong dose or wrong substance — Documented concern for unregulated peptides; CoA helps reduce it. Immune reactions / impurities — FDA has flagged peptide impurity and immunogenicity concerns (FDA safety-risk list). Theoretical cancer-growth concern — Angiogenesis signals in lab studies raise questions for people with cancer history; not established in humans. Unknown long-term effects — No long-term human safety studies. Sports-testing violations — Often prohibited for tested athletes; confirm current WADA/USADA status.

May discuss: Adult men with a soft-tissue injury or recovery goal who are already under a clinician's care; men who want a documented, prescription-based option instead of buying online "research" vials; men willing to report side effects and follow up.

Should avoid: Anyone with active cancer or a recent cancer history, unless their oncologist is involved; tested athletes subject to WADA or league rules; anyone wanting to self-source, self-mix, or self-dose; anyone who expects a peptide to replace imaging, rehab, or orthopedic care.

None of these options is equal to an FDA-approved drug, and none is equal to another. Option — Policy status (as of Nov 2026) — Quality controls — Key catch: Single-ingredient BPC-157 Rx (503A) — Within HHS enforcement discretion if all ten conditions are met; oral use expects documented human oral bioavailability (condition 8) — FDA-registered CGMP manufacturer, CoA, patient-specific Rx, 510(k)-cleared syringe if co-packaged (condition 9) — Still not FDA-approved. Single-ingredient TB-500 Rx (503A) — Within discretion; SQ/IM injection only (Appendix B) — Same — Still not FDA-approved. Two separate single-peptide prescriptions — May fit the policy; clinician and pharmacy decide — Same, per product — No combination trial data. One-vial "Wolverine" blend — Not covered (HHS condition 7, single API) — Varies — Outside the policy. RUO / "not for human consumption" peptides — Not covered; often illegal when marketed for people — None verified — Unknown contents and sterility.

Scoreboard Health plans to offer BPC-157 and TB-500 pathways through a licensed compounding partner. Any prescription is a clinical decision made by a licensed prescriber and the pharmacy, and it has to fit the policy's conditions. Under the current policy (condition 7), that means single-ingredient products, not a combined vial.

1. Did the FDA approve BPC-157 and TB-500? No. HHS announced enforcement discretion for certain 503A compounding. Neither peptide is FDA-approved.

2. What is the Wolverine stack? It's a nickname for using BPC-157 and TB-500 together, usually marketed for recovery from injury.

3. Is a combined Wolverine vial allowed under the new policy? No. Condition 7 of the HHS policy requires a single API from Appendix A in each compounded product, so a two-peptide vial falls outside it.

4. Can I get BPC-157 and TB-500 as separate prescriptions? Separate single-ingredient prescriptions may fit the policy if all ten conditions are met. Your clinician and the pharmacy decide.

5. What routes does the policy allow? Per Appendix B of the HHS policy, BPC-157 acetate may be given subcutaneously, intramuscularly, orally, or topically. For oral products, the compounder is expected to document adequate oral bioavailability in humans (condition 8). TB-500 acetate is limited to subcutaneous or intramuscular injection.

6. Is the policy permanent? No. HHS describes it as interim while FDA builds the 503A bulks list through rulemaking. HHS says it may revisit the policy if safety or quality issues come up.

7. Can I still comment? Yes, for a short time. The notice allows written comments for two weeks after publication, which puts the deadline around November 13, 2026, on regulations.gov (Docket HHS-OASH-2026-0496).

8. Does this make research peptides legal to buy? No. We do not source or recommend research-only products sold for human use. The policy covers 503A compounding from FDA-registered CGMP sources, not RUO products.

9. Did FDA scientists agree? No. Appendix B of the HHS policy states that FDA's Center for Drug Evaluation and Research (CDER) recommended against listing BPC-157 and TB-500, while the Pharmacy Compounding Advisory Committee voted in favor. The AP also covered the disagreement. Advisory votes are not final rules.

10. How should I dose it? That's a question for your prescriber. We don't publish DIY dosing or mixing instructions.

The October 30, 2026 HHS notice gives 503A pharmacies and physicians temporary room to compound BPC-157, TB-500, and several other peptides under strict conditions. It does not approve them, prove they work, cover 503B, or legitimize research chemicals. Because of the single-ingredient rule, the classic one-vial Wolverine blend is outside the policy.

If you're interested in BPC-157 or TB-500, the safer path is a clinician-reviewed, single-ingredient prescription from a documented source, with honest expectations and side-effect reporting through MedWatch.

Write down your injury history, current medications, and goals, then bring them to a licensed clinician. Ask how the HHS conditions apply to you, which pharmacy would compound it, and what would make you stop.

Ready to talk to a clinician? Get a medically supervised consultation and find out which options fit your goals and history. Request a Consultation.